GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » Debt-to-EBITDA

CollPlant Biotechnologies (XTAE:CLGN) Debt-to-EBITDA : -0.17 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CollPlant Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪2.29 Mil. CollPlant Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪9.32 Mil. CollPlant Biotechnologies's annualized EBITDA for the quarter that ended in Dec. 2023 was ₪-70.32 Mil. CollPlant Biotechnologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CollPlant Biotechnologies's Debt-to-EBITDA or its related term are showing as below:

XTAE:CLGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69   Med: -0.49   Max: 4.31
Current: -0.49

During the past 12 years, the highest Debt-to-EBITDA Ratio of CollPlant Biotechnologies was 4.31. The lowest was -0.69. And the median was -0.49.

XTAE:CLGN's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs XTAE:CLGN: -0.49

CollPlant Biotechnologies Debt-to-EBITDA Historical Data

The historical data trend for CollPlant Biotechnologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Debt-to-EBITDA Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.51 -0.69 4.31 -0.18 -0.49

CollPlant Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.27 0.14 -0.18 -0.17

Competitive Comparison of CollPlant Biotechnologies's Debt-to-EBITDA

For the Biotechnology subindustry, CollPlant Biotechnologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Debt-to-EBITDA falls into.



CollPlant Biotechnologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CollPlant Biotechnologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.293 + 9.315) / -23.555
=-0.49

CollPlant Biotechnologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.293 + 9.315) / -70.32
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


CollPlant Biotechnologies  (XTAE:CLGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CollPlant Biotechnologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (XTAE:CLGN) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.